Executive Summary
This Madras High Court judgment addressed a challenge by Raymond Pharmaceuticals Pvt. Ltd. against an order directing it to change its corporate name. The dispute centered on the use of 'Raymond,' which was claimed by another entity (Respondent 3) to be protected under trademark rights and prior incorporation dates. The court upheld the administrative decision, finding no illegality in requiring the petitioner to alter its name.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Madras High Court. Understanding the court's reasoning in M/s.Raymond Pharmaceuticals Pvt. Ltd. vs Union Of India is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
M/S. Liladhar Indarji And Co.vsUnion Of India
The Gujarat High Court disposed of a writ petition filed by M/S. Liladhar Indarji And Co. challenging the rejection of its trademark renewal applications (No. 1502218 and 1502220). Instead of ruling on the merits of the initial rejection, the court granted the petitioner liberty to file a fresh application for renewal. The respondent authority agreed that if the petitioner submits a new request with all prescribed fees, it will be considered within four weeks.
German Remedies Ltd.vsCommissioner Of Central Excise
German Remedies Ltd. challenged the Commissioner's decision regarding the classification and duty rate for its Acetyl Salicylic Acid (ASA) tablets. The dispute centered on whether the product, which was previously classified as a patent/proprietary medicament due to branding, should be treated as a generic product after dropping the trade mark. The Tribunal found that 'ASA' is merely an abbreviation of the chemical name and not a proprietary designation.
Imclone LLCvsAssistant Controller of Patents and Designs, Government of India
Imclone LLC appealed the rejection of its patent application for an antibody targeting PDGFR alpha, which was rejected under Section 3(c) as being a naturally existing substance. The appellant argued that the antibody was generated through complex hybridoma and transgenic mouse technology, making it recombinant and non-naturally occurring. The High Court set aside the rejection order, finding that the claimed invention was not excluded from patent protection.
Levi Strauss & Co.vsLalit Kumar Jaggia
Levi Strauss & Co. filed a suit against Lalit Kumar Jaggia seeking permanent injunctions due to the alleged infringement of its registered trademarks, including 'LEVI'S', 'Two Horse Logo', and associated designs, as well as copyright violation in its labels. The court found the defendant guilty of flagrant infringement and decreed the suit for permanent injunction along with awarding punitive damages.
Arkema FrancevsThe Assistant Controller of Patents & Designs, The Patent Office
Arkema France appealed the rejection of its patent application concerning a 'Heat Transfer Method'. The appellant argued that the rejection relied heavily on a new prior art document (D5) introduced only at the hearing stage. The court set aside the impugned order and remanded the matter for reconsideration, allowing potential amendments under Section 59 if disclosure is deemed inadequate.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.